Currently, there are 4 intravitreal anti-VEGF agents approved by the USA FDA and EMA for treating w-AMD and DME: pegaptanib sodium (Macugen®, Montreal, QC, Canada), ranibizumab (Lucentis® 2013 Genentech, South San Francisco, CA/Roche, Basel, Switzerland), aflibercept (AFL, Eylea®, Regeneron®, Tarrytown, NY, USA, Bayer®, Leverkusen, Germany) and only for w-AMD brolucizumab (Beovu®, Basel, Switzerland 2019); moreover, another anti-VEGF, bevacizumab, is largely adopted in clinical practice as an ‘off-label’ treatment option [1,47]. Here, VEGFA is linked to age-related macular degeneration.